

References

Abdalla MGK and Beattie RB (2000): Ultrasound markers of chromosomal abnormalities. In Progress in Obstetrics and Gynecology Edited by John Studd, Churchill Livingstone ; 14: 24-45.

Abuhamad AZ, Kolm P, Mari G, et al. (1994): *ultrasonographic fetal iliac length measurement in the screening for Down syndrome. Am J Obstet Gynecol.; 171:1063-1067.*

Acacia GI, Barini R, Pinto Junior W, et al (2001): *Nuchal translucency: an ultrasound marker for fetal chromosomal abnormality. Sao Paulo Med J; 4:119(1):19-23.*

Adekunle O, Gopee A and El-Sayed M (1999): *Increased first-trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an un selected antenatal population. Br J Radiol. 72:457-60.*

Baba K (1998). *Development of Three-Dimensional Ultrasound in Obstetrics and Gynecology: Technical Aspects and Possibilities. In 3-D Ultrasound in Obstetrics and Gynecology, edited by Merz E., Lippincott, Williams &Wilkins : pp.3 – 8*

Benacerraf BR, Mandell J, Estroff JA, et al. (2006): Sonographic detection of fetuses with trisomes 13 and 18: accuracy and limitations. Am J Obstet Gynecol ; 158: 404-409.

Bilardo CM, Pajkrt E, De Graaf I, et al.(1998): Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol; 11:401-406.

References

Blaas HG, Eik-Nes OH, Bremnes JB (1998): The growth of the human embryo. A longitudinal biometric assess went from 7 to 12 weeks of gestation. *Ultrasound Obstet Gynecology*; 12:346-54.

Braithwaite JM and Economides DL (1998): Acceptability by patients of transvaginal sonography in the elective assessment of the first trimester fetus. *Ultrasound Obstet Gynecol* ; 9:91-93.

Brand-Saberi B, Floel H, Christ B, et al.(1994a): Alterations of the fetal extracellular matrix in the nuchal oedema of Down's syndrome. *Ann. Anat.*; 176: 539-547.

Brand-Saberi B, Epperlein H and Romanos G E (1994b): Distribution of extracellular matrix components in nuchal skin from fetuses carrying trisomy 18 and trisomy 21. *Cell Tissue Res.*; 227: 465-475.

Bohlandt, S, von Kaisenberg C S, Wewetzer K,et al.(2000): Hyaluronan in the nuchal skin of chromosomally abnormal fetuses. *Hum. Reprod.*; 15: 1155-1158.

Bonilla-Musoles F, et al. (1998): Demonstration of early pregnancy with three-dimensional ultrasound. In Merz B, ed. *3 D Ultrasound in Obstetrics and Gynecology*. Philadelphia: Lippincott Williams & Wilkins.

Bree RL, Marn CS et al. (1990): Transvaginal ultrasonography in the first trimester: embryology, anatomy, and HCG correlation. *Med Ultrasound CT MR*; 12:11.

Carmeliet P, Lampugnani M G, Moons L, et al. (1999): Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. *Cell*; 98: 147-157.

References

Chuang L, Chang CH and Yu CH (2003): Clinical Application of Three Dimensional Ultrasound in Obstetrics: A Review. JPOG; Jan/Feb: 23-33.

Chudleigh T and Thilaganathan B (2004). *Routine second trimester screening-assessing gestational age, in: Obstetric ultrasound how why and when, 3rd ed., Elsevier: pp.99-104.*

Chung BL, Kim HJ, Lee KH (2000): The application of three-dimensional ultrasound to nuchal translucency measurement in early pregnancy (10–14 weeks): a preliminary study. Ultrasound Obstet Gynecol; 15:122.

Clementsich G, Hasenohrl G, Schaffer H, et al. (2001): Comparison between two- and three-dimensional ultrasound measurements of nuchal translucency. Ultrasound Obstet Gynecol; 18:475.

Crossley JA, Aitken DA, Cameron AD, et al.(2002) Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG.;109(6):667-76.

Cuckle H. (2001). Integrating Down syndrome screening. Curr OpinObstet Gynaecol 13(2): 175–181.

Downey DB, et al (2000). *Clinical Utility of Three-dimensional US RadioGraphics 20:559–571.*

Duncan KR and Johnson P (1999): The use of ultrasound in the detection of fetal chromosomal abnormalities. Postgraduate Doctor; 22-(2):36-39.

References

Eppel W, Worda C, Frigo P, et al. (2001): Three- versus two-dimensional ultrasound for nuchal translucency thickness measurements: comparison of feasibility and levels of agreement. *Prenat Diagn*; 21:596.

Fetal medicine foundation. <http://www.fetalmedicine.com/fmf>

Gee A, Prager R, Treece G, et al. (2004): *Processing and Visualizing Three-Dimensional Ultrasound Data. The British Journal of Radiology*; 77 : 186 – 193.

Gilja OH, et al (1999). *Measurements of Organ Volume by Ultrasonography. Proc-Instn-Mech-Engrs*; 213(3) : 247 – 259.

Haak MC and van Vugt JM (2003): Pathophysiology of increased nuchal translucency: a review of the literature. *Hum Reprod Update*; 9(2):175–184.

Hagen – Ansert SL (2001). *Foundation of sonography, in: Textbook of Diagnostic Ultrasonography, 5th ed., edited by Mosby.*

Hill ML(1996): The sonographic detection of trisomies 13, 18 and 21. *Clinical Obstetrics and Gynecology*; 39(4):831-50.

Hyett JA, Perdu M, Sharland GK, et al. (1999): Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. *Br Med*; 318:81-5.

Johnson DD, Pretorius OH and Budorick N (1997): Three-dimensional ultrasound of conjoint twins. *Obstet Gynecology*; 90: 701-2.

Jou HJ, Shih JC, Wu SC, et al.(2001): First trimester Down's syndrome screening by fetal nuchal translucency measurement in Taiwan. *J Formos Med Assoc.*; 100(4): 257-61.

References

Kagan KO, Wright D, Nicolaides KH, et al. (2008): Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A; *Ultrasound Obstet Gynecol*; 31(6):618-24.

Kublickas M, Crossley J and Aitken D (2009): Screening for Down's syndrome in the first trimester: combined risk calculation, methodology, and validation of a web-based system. *Acta Obstet Gynecol Scand.*;88(6):635-8.

Kurjak A, Zodan T and Kupesic S (2000): First trimester Three-dimensional sonoembryology of the first trimester. In: *Clinical application of 3D sonography*. 1st ed. The Parthenon Publishing Group. New York.

Kurjak A and Carrera JM (2004): Early normal pregnancy. In *Donald school Atlas of clinical application of ultrasound in obstetrics and gynecology*. First edition. Jaypee Brothers Medical Publisher Ltd. pp25-51.

Kurjak A and Azumendi G (2007): 3D sonoembryology and fetal anatomy. In: *The fetus in three dimensions*. First ed. *Informa Healthcare*. pp 15-53.

Liang RI, Huaug SE and Chung FM (1997): Prenatal diagnosis of ectopia cordis at 10 weeks of gestation using two dimensional and three-dimensional ultrasonography. *Ultrasound Obstet Gynecology*; 10: 137-9.

Macintosh MCM, Wald NJ, Chard T, et al. (1996): Selective miscarriage of Down's syndrome from 10 weeks of pregnancy (letter). *Br J Obstet Gynaecol* ; 103: 1172-3.

Merz E (1996): Three-dimensional ultrasound in the evaluation of fetal anatomy fetal malformations. *Current Perspectives on The Fetus as a Patient*. Qimrbirth, UK: Parthenon Publishing. 75-87

References

Michailidis GD, Papageorgiou P and Economides DL (2002): Assessment of fetal anatomy in the first trimester using two and three D ultrasound. Br J Radiol; 75:215-9.

Miyabara S, Sugihara H, Maehara, N, et al (1989): Significance of cardiovascular malformations in cystic hygroma: a new interpretation of the pathogenesis. Am. J. Med. Genet.; 34:489-501.

Mulvey SF, Atchison WG, Grimwade JC, et al. (2000): the utilization of nuchal translucency as a prenatal marker of Down syndrome. Aus N Z J Obstet Gynaecol ; 40(11): 423-6.

Nicolaides KH, Sebire N and Snyders R. (1999): The 11-14 week scan: The Diagnosis of Fetal Abnormalities. Parthenon Publishing Group New York; 11: 312-29.

Nicolaides KH. (2004): Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol; 191:45-67 & 243-57.

Nicolaides KH, Kagan KO, Wright D, et al.(2008): Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. ;31(6):618-24.

Nirvikar D, Khurana A (2004): The physical principles and techniques, in: 3D&4D ultrasound a text and atlas. 1st ed. Edited by Jaypee brothers : pp. 1-12.

Nyberg DA, Kramer D, Resta RG, et al. (1993): Prenatal sonographic findings of trisomy 18; review of 47 cases. J Ultrasound Med ; 172:32-35.

References

Orlandi F, Damiani G, Hallahan TW, et al.(1997): First trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. *Ultrasound Obstet Gynecol*; 10: 381-86.

Pandya P, Altman D and Brizot ML (1995): Repeatability of measurement of fetal nuchal translucency thickness. *Ultrasound Obstet Gynecol.*; 5:334-7

Paul C, Krampfl E, Skentou C, et al. (2001): Measurement of fetal nuchal translucency thickness by three dimensional ultrasound. *Ultrasound Obstet Gynecol*; 18:481.

Riccabona M, Nelson TR and Pretorius DH (1996): Three-dimensional ultrasound: accuracy of distance and volume measurements. *Ultrasound Obstet Gynecol* ; 7(6): 429-34.

Sabin (1909): quoted from Van der Putte SC (1975): The development of the lymphatic system in man. *Adv. Anat. Embryol. Cell Biol.*; 51: 3-60.

Sakas G. (1998): *Free-Hand Acquisition, Reconstruction, and Visualisation of Three-Dimensional Data Sets. In 3-D Ultrasound in Obstetrics and Gynecology, edited by Merz E., Lippincott, Williams &Wilkins: pp 17 – 24.*

Schraf DH, Nelson DR and Riccabona M (2001): Prenatal visualization of cranial sutures and fontanelles with three dimensional ultrasonography. *J Ultrasound Med*; 13: 871-876.

Sebire N J, Noble P L, Thorpe, Beeston JG et al.(1997): Presence of the “Lemon” sign at 10-14 week scan. *Ultrasound Obstet Gynecol* ; 10: 403-405.

Seeds JW (1996): *The routine screening obstetrical examination. Clinical Obstetrics and Gynaecology*; 39-4:814-30.

References

- Schuchter K, Wald N, Hackshaw AK, et al.(1998):** The distribution of nuchal translucency at 10-13 weeks of pregnancy. *Prenat Diagn*; 18:281–286
- Spencer K and Carpenter P (1993):** Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. *BJM* ; 307: 764-69.
- Spencer K (2000):** Screening for trisomy 21 in twin pregnancies in the first trimester using free beta hCG and PAPP-A, combined with fetal nuchal translucency thickness. *Prenat Diagn* ; 20(2): 91-5.
- Spencer K, Tul N and Nicolaides KH (2000):** Maternal serum free beta hCG and PAPP-A in fetal sex chromosomal defects in the first trimester. *Prenat Diagn* ; 20(5): 390-4.
- Shaw SW, Hsu JJ, Lee CN, et al. (2008):** *First- and second trimester Down syndrome screening: current strategies and clinical guidelines. Taiwan J Obstet Gynecol*; 47: 157–162.
- Shaw SW, Hsu JJ, Lee CN, et al. (2009):** *Measurement of nuchal volume in the first trimester Down screening using three-dimensional ultrasound. Prenat Diagn* ; 29: 69–73.
- Shipp TD, et al (2001):** *Variation in fetal femur length with respect to maternal race. J Ultrasound Med*; 20:141–144.
- Shipp TD, Bryann B and Beryl B (2006):** Is 3-Dimensional Volume Sonography an Effective Alternative Method to the Standard 2-Dimensional Technique of Measuring the Nuchal Translucency? *Journal of Clinical Ultrasound*. 34(3): 118-122.
- Shih JC, Chen CP and Hsieh FJ (2001):** Three-dimensional ultrasonography in genetic screening and counseling. *Ultrasound Rev Obstet Gynecol*; 1:120-127.

References

Snijders RJ, Souka A, Nicolaides KH, et al (1998): UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet; 352: 343–6.

Souka AP, Snidjers RJM, Novakov A, et al. (1998): Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol; 11: 391-400

Tsai MS, Huang YY, Lee FK, et al.(2001): Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. J Formos Med Assoc.;100(5):319-25.

Von Kaisenberg C S, Brand-Saberi B, Christ B, et al. (1998a): Collagen type VI gene expression in the skin of trisomy 21 fetuses. Obstet Gynecol; 91: 319-323.

Von Kaisenberg CS, Krenn V, Ludwig M, et al.(1998b): Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12±18 weeks and in a trisomy 16 mouse. Anat. Embryol; 197: 105-124.

Von Kaisenberg CS, Nicolaides KH and Brand-Saberi B (1999): Lymphatic vessel hypoplasia in fetuses with Turner syndrome. Hum. Reprod.; 14: 823-826.

Van der Putte SC (1975): The development of the lymphatic system in man. Adv. Anat. Embryol. Cell Biol.; 51: 3-60.

Van Splunder P, Stijnen T and Wladimiroff JW. (1996): Fetal atrioventricular flow-velocity waveforms and their relation to arterial and venous flow-velocity waveforms at 8 to 20 weeks of gestation. Circulation; 94(6): 1372–1378.

References

Van Vugt JMG, Tinnemans BW and Van Zalen-Sproch RM. (1998): Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks gestation. *Ultrasound Obstet Gynecol*; 11:407–409.

Vintzileos AM, Ananth CV, Fisher Aj, et al. (1998): An economic evaluation of the first trimester genetic sonography for prenatal detection of Down syndrome. *Obstet Gynecol* ; 91: 535-39.

Wald NJ, Morris JK, Walker K, et al. (2008): Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. *Prenat.Diagn*; 28(12): 1094–1104.

Weisauer F (2000): Methodology of three dimensional ultrasound. In *Clinical application of 3-D Sonography*, edited by Kurjak A. and Kupesic S., Parthenon Publishing: pp.7 – 23.

Whitlow BJ and Economides DL (1998): The optimal gestational age to examine fetal anatomy and measure nuchal translucency in the first trimester'. *Ultras Obstet Gynecol*; 11:258-261.

Whitlow BJ, Chatzipapas IK and Economides DL (1998): The effect of fetal neck position on nuchal translucency measurement. *BJOG*.; 105:872-876.

Whittle M (1997): Ultrasonographic “soft marker” of fetal chromosomal defects. *BMJ* ; 314:918.

Xu DM, Gruboeck K, Pretorius DH, et al.(2002): Three dimensional ultrasound in obstetrics and Gynecology. New York: Parthenon, 67-74.

Zeanah CH, Dailey JV, Rosenblatt M, et al.(1993): Do women grieve after terminating pregnancies because of fetal abnormalities? A controlled investigation. *Obstet Gynecol* ; 82: 270-75.

References

Zoppi MA, Ibba RM, Putzolu M, et al.(2001): Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older. *Obstet Gynecol* ; 97(6):916-20.

Zoppi MA, Putzolu M, Ibba RM, et al. (2002): First trimester ductus venosus velocimetry in relation to nuchal translucency thickness and fetal karyotype. *Fetal Diagn. Ther.*; 17: 52-57.

Zosmer N, Souter VL, Nicolaides KH, et al. (1999): Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. *Br. J. Obstet. Gynaecol.*; 106:829-833.